USA flag logo/image

An Official Website of the United States Government

Probes for Transient Kinase Complexes

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96183
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
GM090387
Solicitation Year:
N/A
Solicitation Topic Code:
NIGMS
Solicitation Number:
N/A
Small Business Information
Caldera Pharmaceuticals, Inc.
278 DP Road Suite D LOS ALAMOS, NM -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Probes for Transient Kinase Complexes
Agency: HHS
Contract: 1R43GM090387-01
Award Amount: $98,917.00
 

Abstract:

DESCRIPTION (provided by applicant): Most cellular processes are regulated by reversible protein phosphorylation, which is controlled by protein kinases and phosphatases. Caldera Pharmaceuticals and MedChem Partners propose to develop new probes for charac terizing transient protein complexes. MAPK pathways play important roles in cellular differentiation and survival. MAPKs are serine/threonine protein kinases that can phoshorylate both cytoplasmic and nuclear targets. MAPKs are associated with aberrant, ch ronic or hyper-phosphorylation found in cancerous and other diseased tissues. MAPK complexes are difficult to characterize due to the transient nature of kinase-substrate binding interactions. PUBLIC HEALTH RELEVANCE: Caldera Pharmaceuticals and Med Chem Partners propose to develop new probes for characterizing transient protein complexes. MAPK complexes are difficult to characterize due to the transient nature of kinase-substrate binding interactions.

Principal Investigator:

Benjamin P. Warner
5054122345
WARNER@CALDERA-PHARMACEUTICALS.COM

Business Contact:

Benjamin Warner
court@cpsci.com
Small Business Information at Submission:

CALDERA PHARMACEUTICALS, INC.
278 DP Road Suite D LOS ALAMOS, NM 87544

EIN/Tax ID: 120098206
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No